Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The Global BioAccess Fund is a venture capital firm founded in New York, New York, dedicated to partnering with companies in the biopharmaceutical sector. The firm focuses on investing in transformative technologies that address unmet medical needs, particularly in the fields of Oncology, Immunology, Inflammation, cardiovascular diseases, central nervous system disorders, and rare diseases. The fund has established itself as a key player in the healthcare investment landscape.
Currently, the Global BioAccess Fund manages a portfolio of nine companies and has the capacity to invest up to $10 million throughout a company's lifespan. The firm primarily targets early-stage investments, specifically from Series A to Series C rounds. Its team consists of experienced professionals with deep expertise in the biopharmaceutical sector, enabling them to provide valuable insights and guidance to their portfolio companies.
Notable milestones include the successful partnerships formed with various innovative startups, which have contributed to advancements in healthcare. The firm is open to global opportunities, although its primary focus remains on the United States. The Global BioAccess Fund continues to seek out groundbreaking innovations that can significantly impact patient care and treatment outcomes.
The Global BioAccess Fund invests primarily in early-stage companies developing novel therapeutics and devices. Its investment strategy encompasses Series A to Series C funding rounds, with check sizes ranging from $1 million to $10 million. The firm emphasizes transformative technologies in the biopharmaceutical sector, particularly those addressing critical medical needs.
Key sectors of interest include Oncology, Immunology, Inflammation, cardiovascular diseases, central nervous system disorders, and rare diseases. The fund's geographic focus is primarily on the United States, but it remains open to opportunities from other regions. The firm seeks to partner with companies that demonstrate potential for significant impact in healthcare, particularly those innovating in areas with high unmet medical needs.
In their own words, the Global BioAccess Fund aims to support innovations that can significantly improve patient outcomes. The firm looks for founders who are passionate about their work and possess a clear vision for their company's future. Deal structures typically involve close collaboration with portfolio companies to refine business strategies and accelerate growth.
The Global BioAccess Fund's portfolio includes nine notable companies, each contributing to advancements in the biopharmaceutical sector:
These companies represent a diverse range of innovative solutions aimed at addressing significant healthcare challenges. The Global BioAccess Fund's commitment to supporting these ventures underscores its focus on transformative biopharmaceutical technologies.
Bruce Roberts: Managing Partner with extensive experience in the biopharmaceutical sector, previously held leadership roles at several investment firms.
Ted Moon: Managing Partner known for his expertise in healthcare investments, having led multiple successful funding rounds in the biotech space.
Lisa Wisniewski, PhD: Managing Director with a strong background in drug development and regulatory affairs, previously worked at a leading pharmaceutical company.
Sonia Gulati, PhD: Principal specializing in early-stage investments in biopharmaceuticals, with a focus on oncology and immunology.
Dave Praharaj, MD: Senior Associate with clinical experience in drug development, providing insights into medical needs and treatment efficacy.
Kevin Cyr, MD: Research Associate with a background in biomedical research, supporting due diligence and portfolio management.
Michael Krepps: Venture Partner with a history of successful exits in the biotech sector, offering strategic guidance to portfolio companies.
To pitch to the Global BioAccess Fund, startups should send an email to info@globalbioaccess.com. A well-prepared pitch deck is essential, including details about the business model, market opportunity, and team qualifications. The fund prefers concise and clear presentations that effectively communicate the startup's vision and potential.
Response times can vary, but founders can generally expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory. The fund values direct communication and encourages startups to reach out with their proposals.
As of March 2026, the Global BioAccess Fund continues to expand its portfolio, focusing on innovative biopharmaceutical companies. Recent investments include several early-stage firms developing novel therapeutics in oncology and immunology.
The firm has also announced plans to increase its investment capacity, aiming to support more startups addressing critical healthcare challenges. Leadership changes within the team have strengthened its expertise in navigating the complexities of the biopharmaceutical landscape.
What are the investment criteria for the Global BioAccess Fund?
The fund primarily invests in early-stage companies from Series A to Series C rounds, focusing on transformative technologies in the biopharmaceutical sector. Key sectors include Oncology, Immunology, Inflammation, cardiovascular diseases, CNS disorders, and rare diseases.
How can startups apply or pitch to the Global BioAccess Fund?
Startups can reach out via email at info@globalbioaccess.com to initiate discussions about potential investment opportunities. A detailed pitch deck outlining the business model, market potential, and team background is recommended.
What makes the Global BioAccess Fund different from other investors?
The firm combines capital investment with strategic guidance and industry expertise, providing portfolio companies with valuable insights to navigate challenges and accelerate growth.
What is the geographic scope of the Global BioAccess Fund?
While the primary focus is on the United States, the fund is open to partnering with companies from other countries that align with its investment thesis.
What is the typical check size for investments?
The Global BioAccess Fund typically invests between $1 million and $10 million throughout a company's lifespan, depending on the specific needs and growth potential of the business.
What kind of post-investment involvement does the fund have?
The fund actively engages with its portfolio companies, providing strategic guidance and support to help refine business strategies and enhance growth potential.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.